Online Program

My life, our future: A multi-sector partnership to generate genotype and research data within the hemophilia community

Sunday, November 3, 2013

Kati Keebaugh, MPH, American Thrombosis and Hemostasis Network, Riverwoods, IL
Marion Koerper, MD, Department of Pediatrics, University of California, San Francisco Hemophilia and Thrombosis Center, San Francisco, CA
Neil Frick, MS, National Hemophilia Foundation, New York, NY
Barbara Konkle, MD, Puget Sound Blood Center, Seattle, WA
Sally McAlister, RN, BSN, Biogen Idec Hemophilia, Weston, MA
Diane Aschman, MS, American Thrombosis and Hemostasis Network, Riverwoods, IL
OBJECTIVES Hemophilia genotype provides information for prenatal diagnosis, carrier detection, disease severity assessment, and inhibitor risk. Approximately 20% of the U.S. hemophilia community has been genotyped, considerably less than in other developed nations. My Life, Our Future is a community partnership formed to conduct wide-scale genetic testing and generate data to advance scientific research, leading to new treatments. METHODS A multi-sector partnership of non-profits and healthcare entities was formed to make hemophilia genotype analysis available to the U.S. community. American Thrombosis and Hemostasis Network, non-profit with 130+ affiliated hemophilia treatment centers (HTCs), provides HTC provider education, secure infrastructure for data collection, and point of access for data and samples for research. HTCs deliver genetic services, using Puget Sound Blood Center as central genotyping laboratory and sample repository. National Hemophilia Foundation, non-profit with 62 chapters, educates consumers and supports recruitment. Biogen Idec Hemophilia provides scientific expertise and funding. Partners conducted national surveys of patients and providers to assess genetic literacy, identify testing barriers, quantify demand and uncover support needs. RESULTS Through collaboration, the partners are expanding provider capacity to conduct genetic testing and individualize care; increasing awareness about value of genetic testing within the hemophilia community; enabling testing at no/low cost, overcoming insurance barriers; and building data and bio-repository to support future research. A pilot involving 11 HTCs and corresponding chapters is underway. Lessons learned will inform the 2013 national implementation. CONCLUSIONS My Life, Our Future is a novel partnership to address unmet needs for hemophilia genotyping services and research.

Learning Areas:

Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs
Program planning
Public health or related research

Learning Objectives:
Discuss a community partnership to develop a model to address unmet needs within the hemophilia community. Describe stakeholder participation in development of the project goals and processes and in project implementation to provide genotyping services and data for research within the hemophilia community. Demonstrate how the bleeding disorders model applies to other rare disorders.

Keyword(s): Community-Based Partnership, Genetics

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a public health professional. I am American Thrombosis and Hemostasis Network's Manager of Affiliate Services and serve as Project Manager for the National Hemophilia Program Coordinating Center (NHPCC) funded by Health Resources and Services Administration (HRSA) Maternal Child Health Bureau (MCHB). The NHPCC works with eight regional core centers and 135 affiliated hemophilia treatment centers. I also serve as Chair of the My Life, Our Future Healthcare Provider Education Working Group.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.